杭州博之锐

BZR Biotech is a biotechnology company based in Hangzhou, China, specializing in the development of next-generation circular RNA (circRNA) therapeutics and vaccines. Founded in 2021, the company leverages its proprietary BZR-circ platform to create highly stable RNA molecules with prolonged protein expression profiles. This technology aims to overcome the limitations of traditional linear mRNA, such as rapid degradation and the need for high dosages. BZR Biotech's pipeline includes candidates for infectious diseases, oncology, and rare genetic disorders, with a lead program focused on a circRNA-based COVID-19 vaccine. By optimizing both the RNA structure and lipid nanoparticle delivery systems, BZR Biotech seeks to provide more durable and effective treatments for global health challenges.